Irpagratinib
Modify Date: 2024-01-11 12:39:34
Irpagratinib structure
|
Common Name | Irpagratinib | ||
|---|---|---|---|---|
| CAS Number | 2230974-62-4 | Molecular Weight | 570.59 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C28H32F2N6O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of IrpagratinibIrpagratinib (ABSK011) is an orally active inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinase, targeting to FGFR4 (IC50<10 nM). Irpagratinib inhibits the auto-phosphorylation of FGFR4 and blocks signal transduction from FGFR4 to downstream pathway activation. Irpagratinib exhibits high exposure in PK study in mouse, rat and dog, and also shows antineoplastic/anti-tumor activity in subcutaneous xenograft tumor models[1]. |
| Name | Irpagratinib |
|---|
| Description | Irpagratinib (ABSK011) is an orally active inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinase, targeting to FGFR4 (IC50<10 nM). Irpagratinib inhibits the auto-phosphorylation of FGFR4 and blocks signal transduction from FGFR4 to downstream pathway activation. Irpagratinib exhibits high exposure in PK study in mouse, rat and dog, and also shows antineoplastic/anti-tumor activity in subcutaneous xenograft tumor models[1]. |
|---|---|
| Related Catalog | |
| Target |
FGFR4[1] |
| References |
| Molecular Formula | C28H32F2N6O5 |
|---|---|
| Molecular Weight | 570.59 |